{"entity":{"id":"alexander-eggermont","kind":"person","name":"Alexander Eggermont","aka":[],"tldr":"Surgical oncologist who led the EORTC adjuvant ipilimumab and pembrolizumab trials in melanoma.","summary":"Alexander Eggermont is Chief Scientific Officer of the Princess Máxima Center and Professor at Utrecht, and a former President of the EORTC and Director General of Gustave Roussy. A surgical oncologist by training, he specialises in melanoma and adjuvant immunotherapy. He led the EORTC trials that tested adjuvant checkpoint blockade in stage III melanoma: EORTC 18071 of adjuvant ipilimumab and KEYNOTE-054 of adjuvant pembrolizumab, the latter reported in the New England Journal of Medicine as a placebo-controlled trial of pembrolizumab after resection. His work helped establish immunotherapy after surgery in melanoma, and his publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Eggermont%20AM%5BAuthor%5D%20adjuvant%20melanoma"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab","ipilimumab"],"companies":["curie-nki-eortc"],"institutions":["gustave-roussy"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Scientific Officer, Princess Máxima Center; Professor, Utrecht; former EORTC President","institutionId":"curie-nki-eortc","specialisms":["Melanoma","Adjuvant immunotherapy","Surgical oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Eggermont%20AM%5BAuthor%5D%20adjuvant%20melanoma"}],"papers":[{"title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (KEYNOTE-054)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1802357"}]},"route":"/people/alexander-eggermont/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"stage-iii-melanoma","kind":"cancer","name":"Stage III melanoma (after surgery)","route":"/cancers/stage-iii-melanoma/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"curie-nki-eortc","kind":"company","name":"EORTC","route":"/companies/curie-nki-eortc/"}],"institution":[{"id":"gustave-roussy","kind":"institution","name":"Gustave Roussy","route":"/institutions/gustave-roussy/"},{"id":"princess-maxima","kind":"institution","name":"Princess Máxima Center for Pediatric Oncology","route":"/institutions/princess-maxima/"}]}}